NCT06711900
Start here
The phase 3 OptiTROP-Lung06 trial (NCT06711900) tested sac-TMT combined with pembrolizumab in advanced nonsquamous non-small cell lung cancer. The study enrolled 455 patients whose tumors were EGFR/ALK-negative with PD-L1 TPS below 1%, a population that typically responds poorly to immunotherapy alone. The combination significantly prolonged progression-free survival in this group. The results were presented orally at ESMO and published simultaneously in the New England Journal of Medicine. Open questions include the full survival data, the magnitude of benefit by subgroup, and whether the regimen changes first-line practice for PD-L1-negative disease.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickOptiTROP-Lung06 Phase 3: sac-TMT Plus Pembrolizumab Extends PFS in EGFR/ALK-Negative, PD-L1 TPS <1% Advanced Nonsquamous NSCLC
Sac-TMT plus pembrolizumab significantly prolonged PFS in advanced nonsquamous NSCLC in the phase 3 OptiTROP-Lung06 trial (NCT06711900). The study enrolled 455 patients with PD-L1 TPS <1% and EGFR/ALK-negative disease; results were presented orally at ESMO and published simultaneously in the New England Journal of Medicine.
Heat trend for this story
Heat now 11·Peak in the comparable set 19 (Oct 25 20:00)·Change over 24h in the comparable set –·Participants now 2
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.